BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21934203)

  • 1. HBME-1 immunostaining in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
    Rahmani A; Dehghani MZ; Afshar NM; Heidarian H; Tahririan R
    Indian J Pathol Microbiol; 2011; 54(3):460-3. PubMed ID: 21934203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
    Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM; Stern R; Michael CW
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions.
    Wu GP; Zhang SS; Fang CQ; Liu SL; Wang EH
    Cytopathology; 2008 Aug; 19(4):212-7. PubMed ID: 18699986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
    Kundu UR; Krishnamurthy S
    Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
    Wieczorek TJ; Krane JF
    Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative index using Ki-67 index in reactive mesothelial versus metastatic adenocarcinoma cells in serous fluid.
    Moghaddam NA; Rahmani A; Taheri D; Desfuli MM
    Adv Biomed Res; 2012; 1():29. PubMed ID: 23210088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
    Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW; Koivurinne K
    Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
    Conner JR; Cibas ES; Hornick JL; Qian X
    Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic value of thrombomodulin immunolocalization in serous effusions.
    Ascoli V; Scalzo CC; Taccogna S; Nardi F
    Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic use of muscle markers in the cytologic evaluation of serous fluids.
    Afify AM; Al-Khafaji BM; Paulino AF; Davila RM
    Appl Immunohistochem Mol Morphol; 2002 Jun; 10(2):178-82. PubMed ID: 12051638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of antimesothelioma HBME-1 in the diagnosis of inflammatory and malignant pleural effusions.
    Mocanu L; Cîmpean AM; Raica M
    Rom J Morphol Embryol; 2006; 47(4):351-5. PubMed ID: 17392981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
    Duggan MA; Masters CB; Alexander F
    Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
    Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
    Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.